{
    "organizations": [],
    "uuid": "a5258caeba0a333b9e554ba0366bdba03c392b7c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-contravirs-txl-granted-orphan-drug/brief-contravirs-txl-granted-orphan-drug-designation-for-treatment-of-hbv-in-pediatric-population-idUSFWN1QC0V2",
    "ord_in_thread": 0,
    "title": "BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 22, 2018 / 1:31 PM / in 9 minutes BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population Reuters Staff 1 Min Read Feb 22 (Reuters) - Contravir Pharmaceuticals Inc: * CONTRAVIR PHARMACEUTICALS ANNOUNCES TXLâ„¢ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:",
    "published": "2018-02-22T15:30:00.000+02:00",
    "crawled": "2018-02-22T15:48:59.034+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "txl",
        "granted",
        "orphan",
        "drug",
        "designation",
        "treatment",
        "hbv",
        "pediatric",
        "population",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "contravir",
        "pharmaceutical",
        "inc",
        "contravir",
        "pharmaceutical",
        "announces",
        "granted",
        "orphan",
        "drug",
        "designation",
        "treatment",
        "hbv",
        "pediatric",
        "population",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}